Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 2976 |
| PDBID: | 6V4P |
| Chains: | CD_B |
| Organism: | Homo sapiens, synthetic construct |
| Method: | EM |
| Resolution (Å): | 2.80 |
| Reference: | 10.1161/ATVBAHA.119.313671 |
| Antibody | |
| Antibody: | Abciximab Fab |
| Antibody mutation: | No |
| INN (Clinical Trial): | Abciximab(Approved) |
| Antigen | |
| Antigen: | Integrin Beta3 |
| Antigen mutation: | No |
| Durg Target: | P05106 |
Sequence information
Antibody
Heavy Chain: C
Mutation: NULL
| >6V4P_C|Chain C|Abciximab, heavy chain|synthetic construct (32630) EVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSAASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTH |
Light Chain: D
Mutation: NULL
| >6V4P_D|Chain D|Abciximab, light chain|synthetic construct (32630) EIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC |
Antigen
Chain: B
Mutation: NULL
| >6V4P_B|Chain B|Integrin beta-3|Homo sapiens (9606) MRARPRPRPLWATVLALGALAGVGVGGPNICTTRGVSSCQQCLAVSPMCAWCSDEALPLGSPRCDLKENLLKDNCAPESIEFPVSEARVLEDRPLSDKGSGDSSQVTQVSPQRIALRLRPDDSKNFSIQVRQVEDYPVDIYYLMDLSYSMKDDLWSIQNLGTKLATQMRKLTSNLRIGFGAFVDKPVSPYMYISPPEALENPCYDMKTTCLPMFGYKHVLTLTDQVTRFNEEVKKQSVSRNRDAPEGGFDAIMQATVCDEKIGWRNDASHLLVFTTDAKTHIALDGRLAGIVQPNDGQCHVGSDNHYSASTTMDYPSLGLMTEKLSQKNINLIFAVTENVVNLYQNYSELIPGTTVGVLSMDSSNVLQLIVDAYGKIRSKVELEVRDLPEELSLSFNATCLNNEVIPGLKSCMGLKIGDTVSFSIEAKVRGCPQEKEKSFTIKPVGFKDSLIVQVTFDCDCACQAQAEPNSHRCNNGNGTFECGVCRCGPGWLGSQCECSEEDYRPSQQDECSPREGQPVCSQRGECLCGQCVCHSSDFGKITGKYCECDDFSCVRYKGEMCSGHGQCSCGDCLCDSDWTGYYCNCTTRTDTCMSSNGLLCSGRGKCECGSCVCIQPGSYGDTCEKCPTCPDACTFKKECVECKKFDRGALHDENTCNRYCRDEIESVKELKDTGKDAVNCTYKNEDDCV |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| C: ASN31 TYR32 TRP33 HIS35 ALA50 TYR52 ASN55 ASP57 SER59 TYR99 GLY101 TYR102 TYR103 PHE105 D: SER30 ASN31 ASN32 LYS49 TYR50 SER52 GLN53 SER54 SER56 SER67 THR91 ASN92 SER93 TRP94 TYR96 B: TYR122 LYS125 ASP126 LEU128 TRP129 SER130 GLN132 GLU171 ASN175 TYR178 ASP179 MET180 LYS181 THR182 THR183 CYS184 LYS208 SER211 VAL212 MET335 ASP336 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
